Brief: Vyne Therapeutics Announces First Vitiligo Patient Dosed In Phase 1A/B Clinical Trial Of Novel Bet Inhibitor Vyn201

YARROW BIOSCIENCE

09/01/2023 22:41

Jan 9 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES FIRST VITILIGO PATIENT DOSED
IN
PHASE 1A/B CLINICAL TRIAL OF NOVEL BET INHIBITOR VYN201
    * VYNE THERAPEUTICS INC - TOPLINE DATA EXPECTED IN 1H 2023

Source text for Eikon:  ID:nGNX1MpZmk 
Further company coverage:  VYNE.O 
 ((reuters.briefs@thomsonreuters.com;))